Azitra Inc Stock Price, News & Analysis

Azitra (NYSE American: AZTR) has initiated dosing in its Phase 1b clinical trial of ATR-12 for Netherton syndrome, a chronic genetic skin disease. The study will enroll about 12 adult patients with twice-daily treatment for 14 days, focusing on safety and tolerability as primary endpoints. Secondary endpoints include efficacy signals and biomarkers. Azitra expects to report interim safety data in early 2025 and full results in the second half of 2025.

ATR-12 is a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of an active LEKTI protein subunit. The multicenter, randomized, double-blind, vehicle-controlled study (NCT06137157) will treat patients with 109 CFU / g of ATR-12 or its vehicle control twice daily on contralateral body sides.

Azitra (NYSE American: AZTR) has received FDA clearance for an IND application to conduct a Phase 1/2 clinical study of ATR-04, targeting moderate to severe EGFR inhibitor-associated dermal toxicity. This condition affects an estimated 150,000 patients in the US, representing a global market size exceeding $1 billion. ATR-04, a live biotherapeutic product, has shown promise in preclinical studies by reducing IL-36γ and Staphylococcus aureus, key factors in EGFRi-associated skin rash. The company plans to initiate a multicenter, randomized, controlled trial by the end of 2024. This development expands Azitra's clinical pipeline, addressing a significant unmet need for cancer patients receiving EGFR inhibitors who often experience severe skin side effects.

Azitra (NYSE American: AZTR) has screened the first patient for its Phase 1b clinical trial of ATR-12, a potential treatment for Netherton syndrome. The trial aims to enroll 12 adult patients for a 14-day treatment period. Interim safety data is expected in early 2025, with full results anticipated in the second half of 2025.

ATR-12 is a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of an active LEKTI protein subunit. The trial's primary endpoints focus on safety and tolerability, while secondary endpoints assess efficacy signals and biomarkers. Recent preclinical data showed ATR-12's potential to reduce IL-36γ by 93% and significantly decrease protease activity in skin samples.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, reported Q2 2024 financial results and provided business updates. Key highlights include:

1. Completed a $10 million follow-on offering, extending cash runway into 2025.
2. Strengthened global IP portfolio with new patents.
3. Presented positive preclinical data for ATR-04 and ATR-12.
4. Opened Phase 1b trial for ATR-12 in Netherton Syndrome.
5. Anticipates dosing first Netherton syndrome patient with ATR-12 in Q3 2024.
6. Expects to file and clear IND for ATR-04 in Q3 2024.
7. Plans to report initial ATR-12 Phase 1b safety data by year-end 2024.
8. Aims to dose first patient with ATR-04 for EGFRi rash by year-end 2024.
9. Expects topline data from ATR-12 Phase 1b trial in mid-2025.

Financial results: Q2 2024 service revenue $7,500, R&D expenses $1.1M, G&A expenses $1.5M, net loss $2.6M. Cash and equivalents as of June 30, 2024: $0.8M.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has successfully closed its public offering of 16,667,000 shares of common stock at $0.30 per share. The offering raised approximately $5 million in gross proceeds. ThinkEquity acted as the sole book-running manager for the offering. Azitra plans to use the net proceeds for clinical trials, product development, research and development, clinical manufacturing, working capital, and other general corporate purposes. The company has also granted underwriters a 45-day option to purchase up to an additional 2,500,000 shares to cover over-allotments.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has successfully closed its $10.0 million public offering. The offering included 6,665,000 shares of common stock and Class A warrants to purchase up to 13,330,000 shares at a combined price of $1.50 per share and accompanying warrants.

The Class A warrants have an initial exercise price of $1.50 per share, are immediately exercisable, and will expire after five years. Maxim Group acted as the exclusive placement agent. Azitra plans to use the net proceeds for working capital and general corporate purposes. The offering was made pursuant to an effective SEC registration statement, with a final prospectus available on the SEC's website.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has announced the pricing of a $10.0 million public offering. The offering includes 6,665,000 shares of common stock and Class A warrants to purchase up to 13,330,000 shares at a combined price of $1.50 per share and accompanying warrants. The warrants will have an initial exercise price of $1.50 per share, be immediately exercisable, and expire after five years. The offering is expected to close around July 25, 2024. Maxim Group is the exclusive placement agent. Azitra plans to use the net proceeds for working capital and general corporate purposes.

Azitra, Inc. (NYSE American: AZTR) has strengthened its global intellectual property portfolio with newly granted and allowed patents. The company received a U.S. patent for a filaggrin-secreting strain of Staphylococcus epidermidis to treat atopic dermatitis, along with additional patent allowances in the U.S., Canada, and China. These patents protect compositions and methods for treating inflammatory skin diseases using recombinant microorganisms.

The newly issued U.S. patent addresses atopic dermatitis, which affects approximately 16.5 million people in the United States. Azitra is developing live biotherapeutic product candidates for various skin diseases, focusing on precision dermatology. The company's approach involves delivering missing proteins, such as filaggrin, to the skin using engineered bacteria.

Azitra's patent portfolio now includes 4 granted U.S. patents, 14 granted international patents, and numerous pending applications, strengthening its position in the field of precision dermatology.

Azitra, a clinical-stage biopharmaceutical company, announced a reverse stock split of its common stock at a 1-for-30 ratio.

This change will be effective on July 1, 2024, when the stock will begin trading on a split-adjusted basis under the symbol AZTR. At a special stockholder meeting on June 27, 2024, the Board of Directors was granted the discretion to determine the split ratio, which was finalized at 1-for-30. The split will reduce the number of issued common shares from approximately 28.8 million to 960,155. No fractional shares will be issued; instead, stockholders will receive cash for any fractional shares based on the average closing prices of the common stock over the five days prior to the split.

The new CUSIP number for the split-adjusted shares will be 05479L 203. Stockholders with brokerage accounts will see automatic adjustments, and those holding certificated shares may choose to exchange certificates if desired.